Rapid Dose Therapeutics Reports Quarterly Financial Results for First Three Quarters of the 2023 Fis
BURLINGTON, Ontario--(BUSINESS WIRE)--Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), has filed its financial results for the first three quarters of the 2023 fiscal year.Now that the Company has completed the filing of its audited financial statements for the fiscal year ended February 28, 2022...
United Kingdom United States Mark Upsdell Oakland Health Ontario Securities Commission Rapid Dose Therapeutics Corp
Source: pharmiweb.com